Advertisement
U.S. markets open in 3 hours 17 minutes
  • S&P Futures

    5,304.50
    -3.75 (-0.07%)
     
  • Dow Futures

    40,141.00
    -3.00 (-0.01%)
     
  • Nasdaq Futures

    18,483.75
    -20.00 (-0.11%)
     
  • Russell 2000 Futures

    2,135.90
    -2.50 (-0.12%)
     
  • Crude Oil

    81.92
    +0.57 (+0.70%)
     
  • Gold

    2,218.90
    +6.20 (+0.28%)
     
  • Silver

    24.58
    -0.17 (-0.69%)
     
  • EUR/USD

    1.0784
    -0.0046 (-0.42%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    13.00
    +0.22 (+1.72%)
     
  • GBP/USD

    1.2604
    -0.0034 (-0.27%)
     
  • USD/JPY

    151.4470
    +0.2010 (+0.13%)
     
  • Bitcoin USD

    70,625.89
    +561.30 (+0.80%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,974.69
    +42.71 (+0.54%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

NantHealth's(NASDAQ:NH) Share Price Is Down 79% Over The Past Five Years.

Long term investing works well, but it doesn't always work for each individual stock. We don't wish catastrophic capital loss on anyone. Imagine if you held NantHealth, Inc. (NASDAQ:NH) for half a decade as the share price tanked 79%. And it's not just long term holders hurting, because the stock is down 51% in the last year. The falls have accelerated recently, with the share price down 23% in the last three months.

View our latest analysis for NantHealth

Because NantHealth made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

Over five years, NantHealth grew its revenue at 0.7% per year. That's not a very high growth rate considering it doesn't make profits. Nonetheless, it's fair to say the rapidly declining share price (down 12%, compound, over five years) suggests the market is very disappointed with this level of growth. We'd be pretty cautious about this one, although the sell-off may be too severe. We'd recommend focussing any further research on the likelihood of profitability in the foreseeable future, given the muted revenue growth.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

earnings-and-revenue-growth
earnings-and-revenue-growth

We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. You can see what analysts are predicting for NantHealth in this interactive graph of future profit estimates.

A Different Perspective

Investors in NantHealth had a tough year, with a total loss of 51%, against a market gain of about 40%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 12% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. It's always interesting to track share price performance over the longer term. But to understand NantHealth better, we need to consider many other factors. Like risks, for instance. Every company has them, and we've spotted 4 warning signs for NantHealth (of which 1 is significant!) you should know about.

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Advertisement